Efficacy assessment of pemetrexed treatment of an NSCLC case with brain metastasis

V AdamoT FranchinaB AdamoG ScandurraA ScimoneBrain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapyAnn Oncol1711731175200610.1093/annonc/mdj93016608991

T KawabeJH PhiM YamamotoTreatment of brain metastasis from lung cancerProg Neurol Surg25148155201210.1159/00033118822236676

P MulvennaR BartonP WilsonSurvival of patients with non-small cell lung cancer and brain metastasesClin Oncol (R Coll Radiol)23375376201110.1016/j.clon.2011.01.50821392952

C ShihVJ ChenLS GossettSB GatesWC MacKellarLL HabeckLY231514, a pirrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymesCancer Res57111611231997

F BarlesiR GervaisH LenaJ HureauxH BerardD PaillotinPemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)Ann Oncol2224662470201110.1093/annonc/mdr00321321089

RM SchultzVJ ChenJR BewleyEF RobertsC ShihJA DempseyBiological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugsSemin Oncol266873199910598558

H DaiY ChenWF ElmquistDistribution of the novel antifolate pemetrexed to the brainJ Pharmacol Exp Ther315222229200510.1124/jpet.105.09004315987831

W OrtuzarN HannaE PennellaG PengC LangerM MonbergG ScagliottiBrain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancerClin Lung Cancer132430201210.1016/j.cllc.2011.05.00721831719

W SchuetteH TeschH BüttnerT KrauseV SoldatenkovaC StoffregenSecond-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of lifeBMC Cancer1214201210.1186/1471-2407-12-1422244076

CG AzzoliS TeminT AliffS Baker JrJ BrahmerDH JohnsonJL Laskin2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancerJ Clin Oncol2938253831201110.1200/JCO.2010.34.277421900105

D GalettaS PiscontiS CinieriGL PappagalloV GebbiaN BorsellinoInduction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE)Clin Lung Cancer124024062011

A SekineT KatoE HagiwaraT ShinoharaT KomagataT IwasawaMetastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic featuresLung Cancer776469201210.1016/j.lungcan.2011.12.01722335887

M Jamal-HanjaniJ SpicerEpidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brainClin Cancer Res18938944201210.1158/1078-0432.CCR-11-252922167408

GA PesceD KlingbielK RibiA ZouhairR von MoosM SchlaeppiOutcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)Eur J Cancer483773842012

S HeonBY YeapGJ BrittDevelopment of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibClin Cancer Res1658735882201010.1158/1078-0432.CCR-10-158821030498

A BearzI GarassinoM TiseoActivity of Pemetrexed on brain metastases from non-small cell lung cancerLung Cancer68264268201010.1016/j.lungcan.2009.06.01819632738